CORDRAN SP SUMMARY
Cordran® SP Cream
Cordran® (Flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One g dissolves in 72 mL of alcohol and in 10 mL of chloroform.
Cordran is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Published Studies Related to Cordran SP (Flurandrenolide Topical)
Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. [1998.02]
BACKGROUND: Flurandrenolide tape has recently been listed as a group I topical corticosteroid. There are no studies that compare this product to group I ointments in the treatment of steroid-responsive dermatoses. OBJECTIVE: Our purpose was to determine the relative efficacy of flurandrenolide (4 microg/cm2) tape versus 0.05% diflorasone diacetate ointment in plaque psoriasis... CONCLUSION: The efficacy of flurandrenolide tape in the treatment of psoriatic plaques surpasses that of diflorasone diacetate ointment.
Transmittance properties of flurandrenolide tape for psoriasis: helpful adjunct to phototherapy. [2000.10]
BACKGROUND: Flurandrenolide tape is a valuable agent in the treatment of lichen simplex chronicus and in psoriasis. The corticosteroid is helpful for reducing the symptoms and induration of the lichen simplex chronicus lesion, and occlusion of the lesion with the tape reduces the patient's opportunity to rub and scratch the affected area. OBJECTIVES: The purpose of this study was to determine to what extent flurandrenolide tape may block ultraviolet (UV) light and interfere with phototherapy of psoriasis... CONCLUSION: Although flurandrenolide tape may be left in place during PUVA therapy, adjustment of UV dose or removal of the tape is probably needed during UVB phototherapy.
Clinical Trials Related to Cordran SP (Flurandrenolide Topical)
Haelan and Nutrition in Cancer Patients [Recruiting]
1. To determine if treatment with Haelan (fermented soy product) can decrease the severity
of poor appetite measured using a VAS of 0 to 100 mm (0 mm = best, 100 mm = worst) at
week 4 +/- 5 days.
2. To determine if treatment with Haelan can decrease the severity of nausea, fatigue, and
improve patients' overall sense of well being measured using a VAS of 0 to 100 mm (0 mm
= best, 100 mm = worst) at week 4 +/- 5 days.
3. To determine if treatment with Haelan can increase patient's calorie intake, albumin,
pre-albumin, anthropometric measure, lean body mass (measured by bio-impedence
analysis), and weight at week 4+/- 5 days.
4. To determine if treatment with Haelan can decrease patient's FACIT-F and FAACT at week
4+/- 5 days.
5. To assess the feasibility of accrual, and adherence to the Haelan consumption.
1. Determine the plasma isoflavone activity, 12-MTA and 13-MTA of these patients.
2. Correlate the biologic modulation of peripheral blood lymphocyte NF-kB by Haelan with
primary outcome in these patients.
3. To determine if treatment with Haelan can increase patient's functional status at week
4+/- 5 days.